CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.

Human Mesenchymal Stem Cells from Placenta (hPSCs) from Ace Therapeutics are human mesenchymal stem cells (hMSC) isolated from placental tissue, specifically from amnion, decidua, or chorion villi. MSC have been shown to differentiate in vitro into adipocytes, chondrocytes, osteoblasts, myocytes, and β-pancreatic islets cells. They can also transdifferentiate into neuronal cells and hepatocytes.

Human iPSC-Derived Neural Stem Cells are a homogeneous and multipotent population derived from control Human Induced Pluripotent Stem Cells.

Cord blood iPSCs induced with non-viral EBNA1-based episomal vector pEV-SFFV-OS. All cell lines are tested to be free of any transgene vector insertion by PCR analysis and thus are authentic footprint-free iPSCs. These lines have all been passaged long-term (up to P30) without differentiation in optimized human iPSC culture media in the presence of inactivated REF or MEF feeder cells. These lines may have greater propensity to differentiate into Hematopoietic Stem Cells (HSCs) or other mesoderm cells due to epigenetic memory. Great cell model systems for any investigative research work including on iPSCs, HSCs, and disease modeling.Vector: pEV-SFFV-Oct4-2A-Sox2.

The human iPSC line (episomal, CB) from Ace Therapeutics is a type of human induced pluripotent stem cell (iPSC) that was derived from human newborn cord blood (CB) mononuclear cells. The cells were reprogrammed into an embryonic-like pluripotent state using a method involving the introduction of OCT4, SOX2, KLF4, L-MYC, and Lin28 genes through episomal plasmids.

Human Embryonic Hematopoietic Stem Cells (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice. Cells are only guaranteed with the purchase of Ace Therapeutics‘s Media and Ace Therapeutics‘s Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human Placental Derived Mesenchymal Stem Cell are a well-characterized population of adult stem cells. These adult stem cells have a broad therapeutic potential due to their capability to renew and differentiate into various lineages of mature cells that produce fat, cartilage, bone, tendon, and muscle when cultured under specific permissive conditions. These cells are expanded in a Mesenchymal Stem Cell Medium and then cryopreserved at passage 2. The human placental MSC express typical mesenchymal cell surface markers, such as CD105, CD73, and CD90 and are negative for hematopoietic markers including CD34, CD45, and endothelial cell marker CD31.

Human reprogrammed iPSC Cells established from endothelial progenitor cells that derived from peripheral blood.

Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.